Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations

Veterinary Medicine, Immunology, Pharmacotherapy +12

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine · 1997 · 3.2K citations · Full text

Pharmacy, Immunology, Inflammation +12

A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease

SE Plevy, C J Landers, John Prehn et al. · The Journal of Immunology · 1997 · 388 citations · Full text

Life Sciences, Immunology, Pathology +17

Early Postoperative Complications are not Increased in Patients with Crohn's Disease Treated Perioperatively with Infliximab or Immunosuppressive Therapy

Jean‐Frédéric Colombel, Edward V. Loftus, William J. Tremaine et al. · The American Journal of Gastroenterology · 2004 · 383 citations

Medicine, Perioperative Medicine, Surgery +15

Effect of Infliximab on Short-Term Complications in Patients Undergoing Operation for Chronic Ulcerative Colitis

Chelliah Selvasekar, Robert R. Cima, David W. Larson et al. · Journal of the American College of Surgeons · 2007 · 327 citations

Medicine, Internal Medicine, Surgery +15